Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos

Detalhes bibliográficos
Autor(a) principal: Curcio, Pasqualina Curcio
Data de Publicação: 2008
Tipo de documento: Artigo
Idioma: spa
Título da fonte: Cadernos de Saúde Pública
Texto Completo: https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/3540
Resumo: The authors present a model with factors that influence research and development decisions by the pharmaceutical industry: risk of disease transmission and possibility of control; case-fatality and the presence of cure or treatments; income; number of persons who demand the medicine; and opportunity costs for the company. Companies tend to invest in markets with inelastic demand (highly contagious diseases with no possibility of controlling transmission and/or very lethal diseases without treatment) and/or where there is a large population or high per capita income. Companies tend not to invest in markets where marginal costs exceed marginal income, particularly when costs increase permanently as a consequence of rising opportunity costs generated by foregoing profit in other markets. In such cases, policies to subsidize R&D are not effective, and policies must be orientated towards strengthening basic and applied research by public institutions.
id FIOCRUZ-5_88153bc10edd63c42ce39eda7ecac474
oai_identifier_str oai:ojs.teste-cadernos.ensp.fiocruz.br:article/3540
network_acronym_str FIOCRUZ-5
network_name_str Cadernos de Saúde Pública
repository_id_str
spelling Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentosIndustria FarmacéuticaPolíticas de SaludPreparaciones FarmacéuticasMotivaciónThe authors present a model with factors that influence research and development decisions by the pharmaceutical industry: risk of disease transmission and possibility of control; case-fatality and the presence of cure or treatments; income; number of persons who demand the medicine; and opportunity costs for the company. Companies tend to invest in markets with inelastic demand (highly contagious diseases with no possibility of controlling transmission and/or very lethal diseases without treatment) and/or where there is a large population or high per capita income. Companies tend not to invest in markets where marginal costs exceed marginal income, particularly when costs increase permanently as a consequence of rising opportunity costs generated by foregoing profit in other markets. In such cases, policies to subsidize R&D are not effective, and policies must be orientated towards strengthening basic and applied research by public institutions.En el trabajo se desarrolló un modelo con los factores que influyen sobre la decisión de I+D de la industria farmacéutica. Los factores son el riesgo de contagio y la posibilidad de controlarlo; la letalidad y la presencia de curas o tratamientos; el ingreso; el número de personas que demandan y los costos de oportunidad de la empresa. Las empresas invertirán en mercados con demandas más inelásticas (enfermedades muy contagiosas sin posibilidad de controlar la transmisión y/o muy letales sin curas o tratamientos) y/o donde los demandantes tienen elevados ingresos y/o son numerosos. No invertirá en mercados donde sus costos marginales son superiores a sus ingresos marginales, particularmente cuando sus costos incrementan permanentemente como consecuencia del aumento del costo de oportunidad generado por lo que dejaría de ganar en otros mercados. Para estos casos, las políticas de subsidio de la I+D no son efectivas, por lo tanto, éstas deben orientarse al fortalecimiento de las investigaciones, tanto básica como aplicada, realizadas por las instituciones públicas o sin fines de lucro.Reports in Public HealthCadernos de Saúde Pública2008-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlapplication/pdfhttps://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/3540Reports in Public Health; Vol. 24 No. 10 (2008): OctoberCadernos de Saúde Pública; v. 24 n. 10 (2008): Outubro1678-44640102-311Xreponame:Cadernos de Saúde Públicainstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZspahttps://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/3540/7169https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/3540/7170Curcio, Pasqualina Curcioinfo:eu-repo/semantics/openAccess2024-03-06T15:27:40Zoai:ojs.teste-cadernos.ensp.fiocruz.br:article/3540Revistahttps://cadernos.ensp.fiocruz.br/ojs/index.php/csphttps://cadernos.ensp.fiocruz.br/ojs/index.php/csp/oaicadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br1678-44640102-311Xopendoar:2024-03-06T13:04:04.364977Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ)true
dc.title.none.fl_str_mv Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos
title Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos
spellingShingle Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos
Curcio, Pasqualina Curcio
Industria Farmacéutica
Políticas de Salud
Preparaciones Farmacéuticas
Motivación
title_short Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos
title_full Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos
title_fullStr Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos
title_full_unstemmed Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos
title_sort Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos
author Curcio, Pasqualina Curcio
author_facet Curcio, Pasqualina Curcio
author_role author
dc.contributor.author.fl_str_mv Curcio, Pasqualina Curcio
dc.subject.por.fl_str_mv Industria Farmacéutica
Políticas de Salud
Preparaciones Farmacéuticas
Motivación
topic Industria Farmacéutica
Políticas de Salud
Preparaciones Farmacéuticas
Motivación
description The authors present a model with factors that influence research and development decisions by the pharmaceutical industry: risk of disease transmission and possibility of control; case-fatality and the presence of cure or treatments; income; number of persons who demand the medicine; and opportunity costs for the company. Companies tend to invest in markets with inelastic demand (highly contagious diseases with no possibility of controlling transmission and/or very lethal diseases without treatment) and/or where there is a large population or high per capita income. Companies tend not to invest in markets where marginal costs exceed marginal income, particularly when costs increase permanently as a consequence of rising opportunity costs generated by foregoing profit in other markets. In such cases, policies to subsidize R&D are not effective, and policies must be orientated towards strengthening basic and applied research by public institutions.
publishDate 2008
dc.date.none.fl_str_mv 2008-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/3540
url https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/3540
dc.language.iso.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/3540/7169
https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/3540/7170
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
application/pdf
dc.publisher.none.fl_str_mv Reports in Public Health
Cadernos de Saúde Pública
publisher.none.fl_str_mv Reports in Public Health
Cadernos de Saúde Pública
dc.source.none.fl_str_mv Reports in Public Health; Vol. 24 No. 10 (2008): October
Cadernos de Saúde Pública; v. 24 n. 10 (2008): Outubro
1678-4464
0102-311X
reponame:Cadernos de Saúde Pública
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Cadernos de Saúde Pública
collection Cadernos de Saúde Pública
repository.name.fl_str_mv Cadernos de Saúde Pública - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv cadernos@ensp.fiocruz.br||cadernos@ensp.fiocruz.br
_version_ 1798943362071396352

Registros relacionados